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ABSTRACT Although agonists and competitive antagonists presumably occupy overlapping binding sites on ligand-gated
channels, these interactions cannot be identical because agonists cause channel opening whereas antagonists do not. One
explanation is that only agonist binding performs enough work on the receptor to cause the conformational changes that lead
to gating. This idea is supported by agonist binding rates at GABAA and nicotinic acetylcholine receptors that are slower than
expected for a diffusion-limited process, suggesting that agonist binding involves an energy-requiring event. This hypothesis
predicts that competitive antagonist binding should require less activation energy than agonist binding. To test this idea, we
developed a novel deconvolution-based method to compare binding and unbinding kinetics of GABAA receptor agonists and
antagonists in outside-out patches from rat hippocampal neurons. Agonist and antagonist unbinding rates were steeply
correlated with affinity. Unlike the agonists, three of the four antagonists tested had binding rates that were fast, independent
of affinity, and could be accounted for by diffusion- and dehydration-limited processes. In contrast, agonist binding involved
additional energy-requiring steps, consistent with the idea that channel gating is initiated by agonist-triggered movements
within the ligand binding site. Antagonist binding does not appear to produce such movements, and may in fact prevent them.
INTRODUCTION
Conversion of an ion channel from a stable closed state to
an open state is extremely rare unless an external force
drives the channel open. At equilibrium, the ratio of closed
to open channels defines the Gibbs free energy difference
between the two states (Wentworth and Ladner, 1972). The
external force shifts this ratio by altering the free energy
difference. In voltage-gated channels, the electrostatic force
associated with the transmembrane potential moves charges
within the membrane, triggering the opening of the pore
(Hille, 1992). The energy required for these movements can
be calculated from the state transition rate constants mea-
sured in voltage jump experiments. Molecular and fluores-
cence techniques have been used to estimate the number and
location of the charged residues and the distance that they
move, providing a quantitative picture of voltage-dependent
gating (Hille, 1992; Yang et al., 1996; Cha et al., 1999;
Glauner et al., 1999).
The situation is much less clear for ligand-gated channels.
From an experimental standpoint, it has been more difficult
to make rapid agonist applications than rapid voltage steps.
Thus, information about ligand gating has come largely
from steady-state single channel records and from macro-
scopic dose–response curves using relatively slow ligand
applications. Furthermore, gating charge movements, which
are invaluable for studying gating steps in voltage-gated
channels, especially those involving closed states, are not
commonly observed in ligand-gated channels. Although
molecular techniques have identified residues that may par-
ticipate in binding and gating (Amin and Weiss, 1993;
Schmieden et al., 1993; Xu and Akabas, 1996; Changeux
and Edelstein, 1998; Paas, 1998; Wilson and Karlin, 1998;
Boileau et al., 1999; Matulef et al., 1999; Wagner and
Czajkowski, 2001) and electron diffraction measurements
have revealed the structure of a ligand-gated channel to
4.6-Å resolution (Miyazawa et al., 1999), such methods
provide a relatively static picture of channel structure. In
contrast, these channels normally function under highly
nonequilibrium conditions. Kinetic studies thus provide a
valuable link in understanding the relationship between
ligand binding and channel gating.
A few common themes have emerged from studies of
several families of ligand-gated channels. For example,
agonist binding appears to involve multiple, discontinuous
protein domains, often from separate receptor subunits
(Dennis et al., 1988; Schmieden et al., 1992; Vandenberg et
al., 1992; Amin and Weiss, 1993; Stern-Bach et al., 1994;
Paas, 1998; Boileau et al., 1999; Wagner and Czajkowski,
2001). Binding could thus involve a type of chelation or
“induced fit” process (Koshland et al., 1966; Fersht, 1985)
in which separate regions of the receptor come together to
interact with the agonist. A chelation mechanism implies
that the agonist may reciprocally organize separate regions
of the receptor into a relatively rare conformation such as an
open state. Such reciprocal interactions between agonist and
receptor are likely because channel opening is rare in the
absence of agonist (Jackson, 1984), but when channels are
open, agonists can be trapped at the binding site (Benveniste
and Mayer, 1995; Chang and Weiss, 1999).
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Agonist binding rates are often slower than expected for
a diffusion-limited process (Sine and Steinbach, 1986;
Zhang et al., 1995; Akk and Auerbach, 1996; Jones et al.,
1998), implying that an energy-requiring process precedes
or accompanies binding (Jones et al., 1998). Under the
agonist chelation hypothesis, this process would correspond
to structural rearrangements in the binding site that lead to
channel opening. This hypothesis therefore predicts that
ligands capable of opening the channel must bind slower
than the diffusion limit, whereas ligands that do not open the
channel (i.e., competitive antagonists) should bind more
rapidly than agonists.
MATERIALS AND METHODS
Slice preparation and electrophysiology
Sprague-Dawley rats, 14–16 days old, were decapitated and the brains
were transferred to an ice-cold slurry of the extracellular recording solution
containing (in mM): 125 NaCl, 25 NaHCO3, 1.25 NaH2PO4, 2.5 KCl, 2
CaCl2, 1 MgCl2, and 25 D-glucose that was continuously bubbled with 95%
O2/5% CO2. Hemispheres were mounted on a Vibratome (Technical Prod-
ucts, St. Louis, MO) and 300–400-m transverse hippocampal slices were
cut and placed at 37°C for 30 min, after which they were maintained at
room temperature (19–23°C). Outside-out patch recordings were obtained
from granule cells of the dentate gyrus, using pipettes filled with (in mM):
140 KCl, 10 EGTA, 2 MgATP and 10 HEPES. The pH was adjusted to 7.3
with KOH, and osmolarity was adjusted to 310 mOsmol with sucrose.
Patches were voltage-clamped at 60 mV and placed in the stream of a
multibarreled flowpipe array (Vitrodynamics, Rockaway, NJ) mounted on
a piezoelectric bimorph (Vernitron, Bedford, OH). Two computer-con-
trolled voltage sources in series with the bimorph were used to move
solution interfaces over the patch with 10–90% exchange times of 200
s, as measured by the liquid junction current at the open pipette tip after
each experiment. GABAA receptor agonists and antagonists were dissolved
in the perfusion solution, which contained (in mM) 145 NaCl, 2.5 KCl, 2
CaCl2, 1 MgCl2, 10 HEPES (pH adjusted to 7.4 with NaOH and osmolarity
adjusted to 315 mOsmol) and 1 M strychnine. Currents were low-pass
filtered at 1–5 kHz with a four-pole Bessel filter, and digitized at a rate no
less than twice the filter frequency. Concentrated agonist and antagonist
stock solutions were prepared in distilled water and stored at20°C for up
to several months. On the day of each experiment, stock solutions were
thawed and diluted with extracellular saline to the final concentration.
Bicuculline methiodide and SR-95531 [2-(3-carboxypropyl)-3-amino-6-(4-
methoxyphenyl)pyridazinium bromide] were obtained from Research Bio-
chemicals Inc. (Natick, MA), TPMPA [(1,2,5,6-tetrahydropyridine-4-yl)-
methylphosphinic acid] from Tocris (Bristol, U.K.) and SR-95103
[2-(carboxy-3-propyl)-3-amino-4-methyl-6-phenylpyridazinium chloride]
was a kind gift of Dr. M. He´aulme of Sanofi Recherche (Montpellier,
France).
Kinetic analysis
The basic problem in measuring antagonist kinetics is that the antagonist
alone produces no measurable response. Traditional methods have there-
fore examined shifts in the agonist dose–response curve caused by a series
of antagonist concentrations (e.g., Schild analysis; Lew and Angus, 1995).
This procedure allows one to extrapolate the equilibrium antagonist disso-
ciation constant, but does not reveal the individual binding or unbinding
rates. We developed a kinetic method for measuring these rates directly, by
considering the delay induced by antagonist unbinding as a low-pass filter
that distorts a step response to agonist. Kinetic parameters are extracted by
using standard methods from signal processing to compute the form of this
filter (Balmer, 1997).
The experimental protocol is illustrated in Fig. 1, using simulated data.
A preequilibration period with either control solution or antagonist was
followed immediately by a step application of a saturating GABA concen-
tration (10 mM). Depending on the kinetic mechanism of the channel being
studied, the use of saturating agonist may not be necessary, but is more
reliable if there are multiple agonist and antagonist binding sites, and
increases the signal-to-noise ratio of the deconvolution procedure. Control
and antagonist preequilibration trials were interleaved to compensate for
current rundown, and 5–50 traces under each condition were averaged.
With no antagonist preequilibration, the shape of the GABA-activated
current (ICtrl) is governed entirely by the gating kinetics of the GABA-
bound channel. After preequilibration with antagonist, however, the current
(IAnt) consists of two superimposed processes: a component identical in
shape to the control current, arising from those channels that are not bound
with antagonist at the instant of the step, and a delayed component arising
from channels that are initially blocked, but that gradually unbind antag-
onist and become activated during the step.
In control, the saturating GABA step drives all the channels from unbound
into GABA-bound states very rapidly (i.e., the mean dwell time in the unbound
state is10 s), such that ICtrl represents the open probability [POpen(t)] of
an individual channel multiplied by the number of channels (NC) and the
unitary channel current (iC) [i.e., ICtrl  POpen(t)NCiC]. Currents resulting
from delayed channel activation, as occurs during IAnt, arise from the
convolution of ICtrl with the average rate a(t), at which the fraction of
available sites increases due to unbinding of the antagonist,
IAnt at  ICtrl. (1)
Therefore, a(t) can be extracted by using Fourier methods (Balmer, 1997)
to deconvolve the two currents,
at F1FIAntFICtrl , (2)
where F and F1 denote the Fourier and inverse Fourier transforms.
Integration of a(t) then gives A(t), the fraction of receptors available for
binding GABA as a function of time,
At 
0
t
a d, (3)
where both t and  range from time 0 to the end of the data trace. In
practice, the antagonist unbinding time course, A(t), was computed as the
cumulative sum of the inverse discrete fast Fourier transform of the
quotient of the discrete Fourier transforms of averaged current traces with
and without antagonist preequilibration. It should be noted that deconvo-
lution may fail to accurately estimate the unbinding time course if channels
that are simultaneously bound with agonist and antagonist can open with
kinetics different from those in control conditions. This however, would be
incompatible with the traditional view of a competitive antagonist, and is
not supported by our data (Jones et al., 1998; and see Results).
To reduce artifacts that arise when applying Fourier methods to time-
limited signals, data traces were end padded with zeros and multiplied by
a symmetrical sigmoid window, W(t), before deconvolution,
Wt 1
2
 1
2
 tanh  t 1
2
 		
 tanh  t
 1
2
 		, (4)
where , , and 	 are parameters describing the midpoint, width, and
slopes of the window. As different trace lengths were used for different
antagonists, these parameters were adjusted for each trace length to bring
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the edges of the data smoothly to zero with minimal distortion of ampli-
tudes or rise times. If the trace length was T, then typical values were  
0.5T,   0.9T, and 	  0.05T. When tested on simulated noisy data (Fig.
1), windowing greatly improved the precision of kinetic estimates without
significantly altering the average estimated values. Edge effects contami-
nate the deconvolved signals at times greater than0.8T, and we therefore
discarded time points greater than this value before performing kinetic
analysis.
Microscopic rate constants were extracted by least-squares fitting to the
equation,
At P
 P
 P0e
t/u	N, (5)
where P0 and P
 are the probabilities of being available initially (at t  0)
and at steady state (as t3 
), N is the number of antagonist binding sites,
and u is the time constant of antagonist unbinding at each site (Jones et al.,
1998). The fraction of receptors remaining blocked by antagonist is B(t) 
1  A(t). The equilibrium block in the absence of GABA, given by B
 
P
  P0, is concentration dependent and can be fit by the normalized Hill
equation for an antagonist,
B

1
KH/Antagonist	N
 1
. (6)
For a single antagonist binding site (see Results), the microscopic
binding (kon) and unbinding (koff) rate constants follow the relation KH
 koff/kon.
Deconvolution is valid when using impulse responses of kinetically
homogenous, linear, time-invariant systems (Balmer, 1997). Our responses
were driven by steps rather than impulses, and may have arisen from a
kinetically heterogeneous population of channels. Nonetheless, this ap-
proach provided estimates that were indistinguishable from experimental
estimates obtained by other means (see Results) and were very close to the
theoretical values for simulated data. It is also easier to implement and has
better time resolution than previous methods (e.g., Jones and Westbrook,
1997; Jones et al., 1998).
Physical approximations
The diffusion coefficients have not been measured for the ligands tested
in these experiments, nor is the geometry of the binding site known.
Thus, to gain an understanding of the physical nature of interactions of
ligands with the receptor, we made some geometrical approximations
and used these to predict some physical quantities relevant to the
binding interaction.
The most stable in vacuo conformations of the ligands were approxi-
mately planar and fully extended, as deduced from energy minimization
using an MM2 force field (Chem3D; CambridgeSoft Corp., Cambridge,
MA). Using the van der Waals atomic radii, each ligand can fit within an
oblate spheroid having a minor semiaxis, a, and a major semiaxis, b, with
surface area given by (Levy, 1995)
Area 2b2

a2b
b2 a2 log
b
 b2 a2
b b2 a2 . (7)
tions of antagonist. Each current is the sum of 500 single channel traces.
The IC50 current was produced by randomly adding 250 control and 250
antagonist traces. (C) For each antagonist concentration, the actual unbind-
ing time course (solid lines) is well approximated by deconvolving the
ensemble currents from the control current. The y-intercepts are the steady-
state probability of being unbound at the end of the preequilibration.
Symbols are as in (B).
FIGURE 1 A deconvolution-based method for measuring antagonist ki-
netics. (A) Monte Carlo channel simulations with defined parameters were
used to test the accuracy of the method. The model from Jones et al. (1998)
was modified by connecting an antagonist-bound state to the unbound
state, with kon  5  10
7 M1s1 and koff  20 s
1. Openings of a single
channel (upward deflections) were activated by a step into 10 mM GABA,
following preequilibration (Pre) in either control or saturating antagonist
concentration. The latency to the first entry into the unbound (i.e., no
agonist or antagonist bound) state after the step (black dots) was zero for
control but broadly distributed following preequilibration with antagonist.
(B) Ensemble currents from control (open circles) and after preequilibra-
tion with saturating (filled triangles) or IC50 (open triangles) concentra-
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The coefficient of friction, f, of such an object is given by (Lauffer, 1989)
f
6b1 a2/b2
arcsin 1 a2/b2 , (8)
where  is the viscosity of the solvent (0.89 centipoise for water at 25°C).
The diffusion coefficient, D, can thus be computed from Fick’s first law,
D  kBTf
1, where kB is Boltzmann’s constant and T is the absolute
temperature (Lauffer, 1989). If ligand binding is diffusion limited, the
binding rate constant is determined entirely by D and the binding site
geometry, which we conservatively approximated as a spherical pocket
with radius, r, just large enough to accommodate the largest ligand. The
effective encounter radius between the ligand and the pocket is therefore rE
 r  b. The diffusion-limited binding rate is then given by kdiff 
4rEDNA (where NA is Avogadro’s number), which represents the fastest
possible binding rate in the absence of any additional geometric or chem-
ical constraints. Finally, the energies of activation (Ea) and deactivation
(Ed) of the interaction with the binding site can be calculated from Ea 
RT ln(kon/kdiff) and Etot  Ea  Ed  RT ln(koff/kon), where Etot is the
total Gibbs free energy change upon binding (Jones et al., 1998).
Statistics
Unless otherwise indicated, data are reported as mean  SEM. A para-
metric bootstrap (Motulsky and Ransnas, 1987; Lew and Angus, 1995) was
used to test for differences among fitted curves in Fig. 5 A. A series of 1000
fitting runs was executed for each curve. On each run, every point was
replaced by a surrogate, chosen randomly from a normal distribution with
the same mean and standard deviation as the experimental data point. The
log10 of these surrogates was plotted versus log10(koff/kon) and least squares
linear regression was performed. Assuming normally distributed errors in
the raw data, this is equivalent to fitting 1000 data sets independently
drawn from the same population as the actual data. These fitted curves
were averaged to obtain a mean curve, with a 95% confidence interval
extending from the 2.5 to 97.5 percentile values. A significant correlation
can thus be visually ascertained if no straight line with zero slope can be
enclosed within the confidence interval. Similarly, a significant difference
between two data sets exists if no straight line can be simultaneously
enclosed by both confidence intervals. Deconvolution and bootstrapping
were performed with homewritten routines using Matlab 5.2 (The Math-
Works, Natick, MA) on Macintosh computers.
RESULTS
To test the hypothesis that agonist binding involves the
transfer of more energy to the receptor than antagonist
binding, we measured the binding and unbinding rates of a
series of competitive antagonists spanning a wide range of
affinities. The antagonists tested, and their previously re-
ported IC50s for blocking GABAA receptor-mediated cur-
rents, were SR-95531 (0.13 M, Hamann et al., 1988),
bicuculline (0.58 M, Jonas et al., 1998), SR-95103 (20
M, Chambon et al., 1985) and TPMPA (320 M,
Ragozzino et al., 1996). All four antagonists meet the clas-
sical criteria for competitive antagonism in that they cause
concentration-dependent, parallel right shifts in the GABA
dose–response curve.
Antagonist preequilibration alters the step
response to GABA
In outside-out patches, a step application of saturating
GABA concentration activated a smoothly and rapidly ris-
ing current (ICtrl) that began to desensitize during the appli-
cation (Fig. 2). However, after preequilibration with antag-
FIGURE 2 Competitive antagonist unbinding introduces a slow component in the rise of agonist-activated current. Currents were evoked in outside-out
patches by 10 mM GABA, either without preequilibration (control) or after preequilibration in varying antagonist concentrations, as indicated to the left
of the traces. The fast rising phase, similar to that in control, decreased with increasing antagonist concentration. In contrast, the slow component of the
rising phase increased in relative amplitude with antagonist concentration. Note the different time scales and concentration ranges used for the high- and
low-affinity antagonists.
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onist (IAnt) the rising phase consisted of two distinct
components: a rapid and a delayed phase. The rapidly rising
phase was similar to that of the control current but its
relative amplitude decreased with increasing antagonist
concentrations, suggesting that it resulted from channels
that were not initially bound with antagonist. The delayed
phase, however, increased in relative amplitude with in-
creasing antagonist concentrations with a rate of rise that
depended on the identity of the antagonist (compare Fig. 2,
A and B, noting the different time scales). These results
suggest that the delayed component arose from channels
that were initially blocked by antagonist, but then gradually
became available for activation by GABA with a time
course determined by the antagonist unbinding rate.
Extracting microscopic antagonist unbinding
rates by deconvolution
The shape of current activated after preequilibration with
competitive antagonists is influenced not only by the antag-
onist unbinding kinetics, but also by the opening and de-
sensitization kinetics of the GABAA receptor channel. To
separate these processes and obtain the unbinding time
course for each antagonist, we deconvolved the control
currents from those after preequilibration (Fig. 3 and Meth-
ods). In these plots, the y-intercept is the fraction of chan-
nels available for activation by GABA (i.e., in unbound
states), and therefore depends on the antagonist concentra-
tion. The relaxation directly reveals the antagonist unbind-
ing time course, and was fitted with Eq. 5 (solid lines) to
determine the number of binding sites (N) and the unbinding
time constant at each site (u). For all four antagonists, the
best fits (i.e., minimum 2 with N constrained to be an
integer) were obtained with a single binding site (N 1), as
previously found for SR-95531 in cultured neurons (Jones
et al., 1998; and see below). This result is apparent in the
plots of Fig. 3, which lack the sigmoidicity expected if
unbinding from multiple sites was necessary to achieve full
channel availability. The reciprocal time constants thus pro-
vide the microscopic antagonist unbinding rates (koff 
FIGURE 3 Deconvolution reveals the antagonist unbinding time course and the number of binding sites. The plots show the results of deconvolving
currents (obtained as in Fig. 2) with antagonist preequilibration from those without preequilibration for four different antagonists. Each set of points is data
from a single patch and has been offset so that P
  1. Note the different time scale and concentration range used for each antagonist. The y-intercepts
indicate the steady-state fraction of available (i.e., antagonist-unbound) channels at the instant of the GABA step. The number of antagonist binding sites
(N) and the time constants of antagonist unbinding (u) were obtained by fitting the three traces in each graph with Eq. 5 (solid lines). In every case, the
best fit was obtained with a single binding site.
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1/u), and were (in s
1) 6.5  0.3 for SR-95531 (n  11
patches), 61.6  9 for bicuculline (n  6), 383  38 for
SR-95103 (n  19) and 2146  159 for TPMPA (n  30).
The parameters for SR-95531 measured by deconvolution
were indistinguishable from the values of koff  7.4  0.5
s1 and N  1 (p  0.2; n  4), measured in the same
preparation using an independent method described in Jones
et al. (1998). As expected for an unbinding process, the
relaxation rates were independent of antagonist concentra-
tion (R2  0.05) and results were therefore pooled across
different concentrations for each antagonist.
The equilibrium occupancy by antagonist in the absence
of GABA was obtained by plotting the y-intercepts from
Fig. 3 versus antagonist concentration (Fig. 4, top). Consis-
tent with competitive antagonism, channel availability ap-
proached zero as antagonist concentration was increased. To
determine the affinity constant (KH) and confirm the num-
ber of antagonist binding sites, the data were fitted with the
normalized form of the Hill equation for an antagonist (Eq.
6), in which N was constrained to be an integer. Consistent
with the nonequilibrium analysis of Fig. 3, the best fits to
the equilibrium data for all four antagonists indicated a
single binding site (Fig. 4, bottom). Therefore, KH repre-
sents a microscopic affinity constant (i.e., the concentration
at which the probability of each binding site being occupied
by antagonist is 0.5), and was (in M) 3.3  107 for
SR-95531, 1.2  106 for bicuculline, 8.5  106 for
SR-95103, and 4.3  104 for TPMPA. The presence of a
single binding site allows for the direct calculation of mi-
croscopic binding rates (kon  koff/KH), which were (in
M1s1) 1.8  0.16  107 for SR-95531, 5.0  0.9  107
for bicuculline, 4.3  0.5  107 for SR-95103, and 5.0 
0.4  106 for TPMPA. These data show that, in contrast to
their very different unbinding rates and affinity constants,
the four antagonists tested had binding rates that differed by
one order of magnitude at most.
Agonists and antagonists have separate
association mechanisms
The binding and unbinding rates of GABAA receptor ago-
nists are strongly correlated with each other, with the affin-
FIGURE 4 The equilibrium occupancy by antagonist in the absence of GABA. (A) Antagonist dose–response curves were constructed by plotting the
y-intercepts from plots like those in Fig. 3 versus antagonist concentration. The solid lines are fits of the Hill equation with the number of sites (N)
constrained to 1. (B) The chi square values for the fits to the dose–response data, plotted against the number of assumed sites (N). In every case, the chi
square increased as the constrained N was increased away from a value of 1 (open circles). When N was unconstrained (filled circles), the minimum chi
square occurred for N near 1.
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ity constant, and with agonist length (Jones et al., 1998).
These correlations can be quantitatively explained if agonist
binding promotes movements within the binding site that
drive channel gating. Under this hypothesis, competitive
antagonists should show a different profile of correlations.
Fig. 5 A shows that this appears to be the case. Unbinding
rates for both the agonists (open squares) and antagonists
(closed squares) were steeply correlated with their affinity
constants. Agonist binding rates (open circles) were also
correlated with affinity, whereas antagonist binding rates
(closed circles) were not (i.e., the slope of the fitted line was
not significantly different from zero). The most conserva-
tive interpretation of these data is simply that agonists and
antagonists interact with the binding site according to dif-
ferent mechanisms. However, these data also reveal a con-
nection between events occurring at the ligand binding site
and those governing channel gating. The work done on the
receptor by agonist binding is closely related to the activa-
tion energy for binding, Ea, previously estimated to be 4–8
kcal/mol for each agonist molecule (Jones et al., 1998).
Those estimates contained slight inaccuracies due to an
error in the calculation of kdiff, and to using a single arbi-
trarily chosen diffusion coefficient, D, for all agonists. To
allow a comparison between agonists and (generally larger)
antagonists, however, a uniform approach to choosing dif-
fusional parameters is necessary. We therefore recomputed
D, kdiff and Ea for all ligands tested using ligand-specific
sizes measured from molecular models, and basic geomet-
rical and physical principles (see Materials and Methods).
Each ligand was treated as an oblate spheroid having minor
and major semiaxes a and b, where ligand length  2b.
These values were [in Å for (a, b) pairs] (2.46, 4.55) for
GABA, (1.55, 4.36) for muscimol, (1.81, 4.21) for THIP,
(1.73, 3.90) for -alanine, (2.28, 8.12) for SR-95531, (3.07,
7.32) for bicuculline, (2.75, 7.17) for SR-95103 and (2.82,
4.73) for TPMPA. The range of corresponding diffusion
coefficients was 4.0–7.8  106 cm2s1, yielding kdiff
values ranging from 4.9 to 7.1  109 M1s1. The activa-
tion energies, Ea, were (in kcal/mol) 4.2  0.5 for GABA,
4.3  0.2 for muscimol, 5.7  0.1 for THIP, 7.5  0.1 for
-alanine, 3.3  0.1 for SR-95531, 2.8  0.5 for bicucul-
line, 2.9  0.6 for SR-95103 and 4.3  0.5 for TPMPA
FIGURE 5 Agonists and antagonists bind via fundamentally distinct mechanisms. (A) The log10 of binding (circles) and unbinding (squares) rate
constants for agonists (open; taken from Jones et al., 1998) and antagonists (filled) are plotted against log10 of their affinity constants. From left to right,
the antagonist points are SR-95531, bicuculline, SR-95103, and TPMPA; and agonist points are muscimol, GABA, THIP, and -alanine. Unbinding rates
for both agonists and antagonists were steeply correlated with affinity. Unlike the agonists, antagonist binding rates are relatively constant regardless of
affinity. The dashed lines represent 95% confidence limits of the solid lines, which are the mean of 1000 bootstrap fits of the equation log10k  a
log10(koff/kon)  b. The best fitting (a, b) pairs were (0.55, 4.1) for kon(Ag), (0.24, 6.1) for kon(Ant), (0.46, 4.1) for koff(Ag), and (0.64, 5.9) for koff(Ant).
The line describing antagonist binding rates is significantly different from that for agonist binding but not significantly different from a line with zero slope
(see Methods). (B) Activation energies, Ea, of all eight ligands (agonists: white; antagonists: black). With the exception of TPMPA, antagonists require less
activation energy than agonists. (C) The energy remaining after subtracting the energy required to dehydrate the entire ligand surface (Ea  Ehyd; see text).
Ehyd was (in kcal/mol) 3.46 for GABA, 2.95 for muscimol, 2.83 for THIP, 2.45 for -alanine, 9.97 for SR-95531, 8.54 for bicuculline, 8.07 for SR-95103,
and 3.84 for TPMPA. The energy of dehydration is more than enough to account for the activation energy of the antagonists. Complete dehydration of the
agonists, however, does not involve enough energy to account for their activation energy.
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(Fig. 5 B). Three of the four antagonists tested had faster
binding rates and lower activation energies than the ago-
nists. However, the structurally atypical antagonist TPMPA
binds more slowly than the others, overlapping the high end
of the agonist binding rates and the low end of agonist
activation energies.
All of the ligands tested had binding rates 2–5 orders of
magnitude slower than expected for a diffusion-limited pro-
cess, and therefore have nonzero activation energies. Some
of this energy may be expended in causing conformational
changes in the receptor, but, because there is a local order-
ing of water at hydrophobic surfaces (Fersht, 1985; Lauffer,
1989), some of the activation energy could also represent
that required to displace water molecules from the interface
between the ligand and receptor. Hydrophobic energy is
proportional to the surface area of interaction (22.5 cal
M1 Å2) and is similar to that for creating a cavity of the
same area in water (Fersht, 1985). We thus estimated the
maximal activation energy due solely to such displacement
(Ehyd). Figure 5 C shows the activation energy that remains
unaccounted for if the entire ligand surface area must be
dehydrated before binding. With the exception of TPMPA,
such dehydration would easily cost enough energy to ex-
plain why antagonist binding is not strictly diffusion lim-
ited. Indeed, the negative energies for three of the antago-
nists in Fig. 5 C suggests that only a portion of the
antagonist surface forms an interface with the receptor.
However, even if the entire agonist surface had to be dehy-
drated, an additional energy-requiring process must be in-
voked to account for the slow agonist binding rates.
DISCUSSION
Classical pharmacology draws a sharp distinction between
the ability of a ligand to interact with its binding site
(affinity) and its ability to promote a physiological response
(efficacy). In contrast, because events at the binding site
cause the response, the factors governing affinity and effi-
cacy must somehow interact. We explored this interaction
by examining ligands at the GABAA receptor with maxi-
mum efficacy (full agonists) and those with zero efficacy
(competitive antagonists) and found a fundamental differ-
ence: agonists tend to expend more work during binding
than do antagonists. This difference between the energetic
requirements of agonists and antagonists is consistent with
a mechanism in which agonist binding is slowed by the
work expended in altering the conformation of the binding
site, whereas antagonist binding performs little work on the
receptor. We note that TPMPA may be an exception to this
generalization.
Possible sources of error
Our analysis depends mainly on accurate measurement of
the microscopic binding and unbinding rates of agonists and
antagonists. The deconvolution-based method yields rate
constants and numbers of binding sites indistinguishable
from those obtained for SR-95531 using a more direct
approach (Jones et al., 1998), suggesting that the simplify-
ing assumptions underlying the deconvolution did not in-
troduce large errors. The direct approach is also not practi-
cal for very rapidly unbinding antagonists such as SR-95103
or TPMPA.
Interestingly, we observed only a single antagonist bind-
ing site using either steady-state or relaxation methods,
consistent with Hill coefficients near unity obtained by
others in physiological experiments with GABAA receptor
antagonists (Kemp et al., 1986; Hamann et al., 1988; Duit-
toz and Martin, 1991; Ueno et al., 1997; Jonas et al., 1998).
This result is perplexing because there are clearly multiple
agonist binding sites (Constanti, 1977; Bormann and
Clapham, 1985; Macdonald et al., 1989; Twyman et al.,
1990). This apparent discrepancy remains unexplained but
suggests that, if multiple antagonist sites exist, only one
contributes to the inhibition of channel function in a rate-
limiting manner.
A potentially more problematic issue is whether the an-
tagonists are purely competitive; that is, they occupy the
binding site but cause no other actions at the receptor.
Several observations argue that this is the case. The antag-
onist dose–response curves approach zero at high concen-
trations and both these and the unbinding relaxations are
entirely consistent with a pure competitive mechanism that
follows exactly the analytical predictions for a two-state
process. Significant deviations from this behavior should
have been observed if multiple (e.g., desensitized) states
were involved in determining antagonist kinetics. Further-
more, some manipulations that increase the extent of mac-
roscopic desensitization also increase the rate of antagonist
unbinding (Jones and Westbrook, 1997), opposite to what is
expected if the antagonist-bound channel visits desensitized
states (but see Ueno et al., 1997).
The sets of points in Fig. 5 A, especially those for antag-
onists, display a degree of curvature that suggests that linear
fitting may not be the best way of quantifying the relation
between microscopic rates and affinity when comparing
different ligands. This curvature is not due to multiple
binding steps in the antagonist binding reaction because
such steps should have been apparent in the behavior of
each antagonist, as a sigmoidicity in the unbinding time
course (Fig. 3) and as a slope greater than unity in the
equilibrium dose–response curve (Fig. 4). However, not one
of the antagonists displayed any evidence of a multistep
reaction. This curvature instead probably reflects differ-
ences in energetics between ligands of different structures
as they interact with the same binding site, and is predicted
by the nonlinear dependence of intermolecular forces on the
distance separating interacting particles (e.g., Jones et al.,
1998). Thus, differences in activation and deactivation en-
ergies should vary nonlinearly with the degree of spatial
Kinetics and Energetics of GABAA Receptor Ligands 2667
Biophysical Journal 81(5) 2660–2670
mismatch between ligand and receptor structures. An exact
formula for this relation requires more detailed structural
information about the binding site than is presently avail-
able.
A final consideration is that TPMPA is clearly unlike the
other antagonists. It binds as slowly as some of the agonists,
and we cannot exclude the possibility that measurements of
even lower-affinity antagonists might reveal a significant
correlation between antagonist binding rates and affinity.
Such a correlation would render the differences between
agonists and antagonists to be a matter of degree, rather than
of quality. Thus, an alternative interpretation would be that
the agonist and antagonist rate constants actually arise from
identical parent distributions (i.e., lie along the same lines in
Fig. 5 A), and that the statistical differences between them
are caused by grouping them according to our prior knowl-
edge that the two classes of ligands have distinct pharma-
cological actions. We do not believe that this is the case,
because omission of the TPMPA data greatly accentuates
the differences between agonist and antagonist kinetics on
the whole. Nonetheless, the unusual profile of TPMPA may
reflect an atypical mechanism of antagonism, for example,
an action as an extremely weak partial agonist.
Physics of ligand binding
A simple physical model can quantitatively account for the
correlations among length, binding/unbinding rates, and af-
finity of agonists at the GABAA receptor (Jones et al.,
1998). Briefly, the binding pocket contains flexible “arms”
that must leave their resting position and move closer to the
agonist to form bonds with the agonist molecule. This
process requires energy (i.e., the activation energy for the
binding reaction) that increases with the distance moved.
Small agonists require larger movements, entailing larger
activation energies and slower binding. Because only a
fraction of this energy is recovered upon bond formation
with the agonist, the system remains at a higher total energy
when bound with a small agonist compared to a larger one.
Thus small agonists have lower deactivation energies and
faster unbinding rates. A satisfying aspect of this model is
that it requires the agonist to perform work on the receptor
during the binding process, in keeping with the intuition that
the agonist must “do something” to the receptor to open the
channel. Furthermore, this model predicts that ligands re-
quiring no activation energy will not be capable of opening
the channel because they cause no movement. Our findings,
that three of the four competitive antagonists bind more
rapidly and require less activation energy than agonists, is
consistent with that prediction. TPMPA, however, is struc-
turally more similar to the agonists than antagonists, and
therefore resembles them in its energetic profile, which, in
our analysis, was computed on the basis of geometry alone,
without regard to ligand-specific chemical groups or charge
distribution. Geometry therefore cannot be the only factor
determining ligand efficacy.
Unlike the agonists, the relation between antagonist
length and kinetics is not straightforward (Fig. 6). For
example, the GABA-like regions of SR-95531 and SR-
95103 are identical despite their very different kinetics. For
bicuculline, it is difficult even to identify a GABA-like
region unambiguously. Similarly, the contribution of antag-
onist charge is not clear, but no unique charge structure
appears to be required to confer either agonist or antagonist
function (Chambon et al., 1985). However, the prevalence
of aromatic groups among the antagonists suggests that
hydrophobic interactions rather than movements in the
binding site, may be rate-limiting for antagonist binding
(Andrews and Johnston, 1979; Chambon et al., 1985). Con-
sistent with this idea, we found a strong linear correlation
between hydrophobic energy and the equilibrium free en-
ergy for antagonists (Etot  0.69  Ehyd  1.9; R
2 
0.96; not shown) but not for agonists (R2  0.67). For
antagonists, most of this correlation was due to the deacti-
vation energy rather than the activation energy (R2: 0.82
versus 0.67). This situation was reversed for the agonists,
which showed a weaker correlation for deactivation energy
than for activation energy (R2: 0.49 versus 0.78). It therefore
seems likely that antagonist binding is governed largely by
diffusion- and dehydration-limited events. Binding appears
to proceed as fast as diffusion can bring antagonist into the
binding site and water can be displaced, with the stability of
the bound complex being largely due to hydrophobic inter-
actions with the receptor. Agonist binding, in contrast, ap-
pears to involve more specific interactions with the receptor,
and may be additionally delayed by the time required for the
binding site to flex into an appropriate conformation. The
stabilization of this conformation by the agonist may com-
prise the useful work that results in channel gating.
FIGURE 6 The chemical structures of the GABAA receptor agonists and
antagonists.
2668 Jones et al.
Biophysical Journal 81(5) 2660–2670
The function of the GABA binding site
GABAA receptors are subject to positive and negative mod-
ulation at a number of distinct sites that are functionally
coupled to each other. Interestingly, positive modulators
generally enhance the affinity of other positive modulators
but reduce the affinity of negative modulators, and vice
versa. For example, barbiturate binding increases agonist
and benzodiazepine affinity but decreases antagonist affin-
ity (reviewed in Olsen, 1982; Olsen et al., 1991). These
observations suggest not only that modulators affect chan-
nel gating via common structural elements, but also that
binding sites scattered over the receptor surface may inter-
act in a coordinated manner. One possible view of receptor
function is that there is an “active” conformation to which
positive modulators bind tightly regardless of their site, and
a “resting” conformation to which negative modulators bind
tightly. Interestingly, some antagonists can noncompeti-
tively inhibit currents activated by anesthetics in the ab-
sence of GABA (Ueno et al., 1997). These observations
may be explained by antagonists stabilizing the receptor in
a conformation structurally similar to the unbound confor-
mation (but see also Ueno et al., 1997).
The active and resting conformations are probably sepa-
rated by subtle structural differences rather than large rear-
rangements. First, the work associated with binding of two
GABA molecules is equivalent to the formation of only a
few hydrogen bonds, but is sufficient to fully activate the
channel (Jones et al., 1998). Ligands that do more work do
not yield a higher efficacy, suggesting that there is a low
threshold for full-channel activation. Second, this amount of
work may produce a total movement in each binding site of
only1.2 Å; a fraction of the length of the GABA molecule
itself (Jones et al., 1998). Downstream movements associ-
ated with gating might be even smaller if the transduction of
binding energy to the gate is not 100% efficient.
The available kinetic evidence is consistent with a GABA
binding site that flexes upon binding an agonist. This move-
ment is small but alters the structure of the protein enough
that the central pore becomes conductive. Structural studies
suggest that GABA interacts directly with three residues in
a -strand on the  subunit (Boileau et al., 1999) and also
with several residues from different regions on the  subunit
(Amin and Weiss, 1993; Wagner and Czajkowski, 2001).
Both kinetic and structural data therefore support the idea
that agonist binding brings together separate domains of the
receptor in a chelation-like reaction, reorganizing the recep-
tor structure to open the ion pore. In contrast, the activation
energy of antagonist binding can be explained by dehydra-
tion, with little or no energy left over to alter the receptor
structure. Finally, if channel opening is associated with the
drawing together of residues on the  and  subunits, the
large hydrophobic regions of the antagonists (or the bulky
methylphosphinic acid group in the case of TPMPA) may
inhibit anesthetic-induced gating by sterically hindering this
movement, thus stabilizing the resting conformation of the
binding site.
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